News

NICE says NO to ibrutinib again and asks company to put the drug forward for new Cancer Drugs Fund

We are extremely disappointed with the second preliminary decision by the National Institute for Health and Care Excellence (NICE) not to recommend ibrutinib to treat relapsed refractory CLL, this preliminary decision also confirms NICE are ‘minded’ not to recommend ibrutinib for treating patients with a 17p deletion or TP53 mutation.

This latest draft guidance is set out in a second appraisal consultation document    

Recommendations:

CLLSA help line for people living with and affected by CLL, family & friends – CALL 0800 977 4396

We know that a diagnosis of CLL can change everyday life for CLL patients and their families.  We know that it is often difficult to talk to loved ones, family or friends about your condition.

Talking to someone who is a fellow patient can help inform and ease the anxiety.  If you have been recently diagnosed, are waiting for your first chemotherapy, need information or just want to talk………..

 

Fundraiser for CLLSA and Leukaemia & Lymphoma Research (Bloodwise) is Cycling from Lands’ End to John O' Groats

 

Support Jules with his marathon bike ride this summer as he raises funds for CLLSA and Bloodwise. 

“You may all know that I raise funds for Leukaemia and Lymphoma Research but there is another charity that we all couldn't do without; The CLLSA - I think we would all agree that we would be a lot worse off without them.

CLLSA response to the NICE negative draft recommendation for Ibrutinib to treat Chronic Lymphocytic Leukaemia (CLL)

We are extremely disappointed with the preliminary decision by the National Institute for Health and Care Excellence (NICE) not to recommend Imbruvica® (Ibrutinib) for treating chronic lymphocytic leukaemia (CLL) patients who have had at least one prior therapy or, for people with 17p deletion or TP53 mutation and for whom chemo-immunotherapy is unsuitable.     

CLL patients have historically had limited access to effective and innovative treatments. If this decision is not reversed following the next consultation process, the health of CLL patients could be seriously affected.